404
Views
19
CrossRef citations to date
0
Altmetric
Articles

Synthesis, characterization, and antitumor properties of ruthenium(II) anthraquinone complexes

, , &
Pages 177-189 | Received 21 Jun 2015, Accepted 17 Sep 2015, Published online: 22 Jan 2016
 

Abstract

Three new Ru(II) complexes, [Ru(dmb)2(ipad)](ClO4)2 (dmb = 4,4′-dimethyl-2,2′-bipyridine, ipad = 2-(anthracene-9,10-dione-2-yl) imidazo[4,5-f][1,10]phenanthroline, 1), [Ru(dmp)2(ipad)](ClO4)2 (dmp = 2,9-dimethyl-1,10-phenanthroline, 2), and [Ru(dip)2(ipad)](ClO4)2 (dip = 4,7-diphenyl-1,10-phenanthroline, 3), have been synthesized and characterized. The three Ru(II) complexes intercalate with the base pairs of DNA. The in vitro antiproliferative activities and apoptosis-inducing characteristics of these complexes were investigated. The complexes exhibited cytotoxicity against various human cancer cell lines. BEL-7402 cells displayed the highest sensitivity to 1, accounted for by the greatest cellular uptake. Complex 1 was shown to accumulate preferentially in the nuclei of BEL-7402 cells and cause DNA damage and induce apoptosis, which involved cell cycle arrest and reactive oxygen species generation.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by Guangdong Province Youth Innovation Projects Foundation [grant number 2014KQNCX140]; Guangdong Province Medical Research Fund [grant number B2014204]; and National Natural Science Foundation of China [grant number 81403317].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.